CPA Applauds Sen. Cotton for Introduction of the ‘PILLS Act’ – Legislation to Incentivize Domestic Production of Lifesaving Medicines

CPA Applauds Sen. Cotton for Introduction of the ‘PILLS Act’ – Legislation to Incentivize Domestic Production of Lifesaving Medicines

A smart policy like the ‘PILLS Act’ would prioritize domestic production of essential generics. It’s precisely the market signal needed to attract serious investment and rebuild the industry at home.

CPA Releases Comments on Section 232 Investigation of Pharmaceutical Imports

CPA Releases Comments on Section 232 Investigation of Pharmaceutical Imports

As the leading organization advocating for reshoring the generic drug industry, CPA’s submission documents how extreme overreliance on foreign pharmaceutical supplies—especially active pharmaceutical ingredients (APIs) and critical injectable drugs from China and India—poses an urgent threat to U.S. national security and patient safety.

CPA Expresses Concern over U.S.-UK Trade Framework’s Impact on U.S. Steel Industry

CPA Expresses Concern over U.S.-UK Trade Framework’s Impact on U.S. Steel Industry

While CPA recognizes certain positive elements of the deal — including a historic pivot towards prioritizing tariff revenue as well as industrial protection — it remains concerned about dangerous precedents being set by sacrificing domestic production while pursuing foreign market access.

CPA Applauds Trump Administration for Prioritizing Revenue and Protection in New U.S.-UK Trade Deal

CPA Applauds Trump Administration for Prioritizing Revenue and Protection in New U.S.-UK Trade Deal

By maintaining the 10% baseline tariff and capping UK auto imports at 100,000 vehicles per year before higher tariffs apply, the administration is demonstrating that trade policy can and should be used to protect and rebuild domestic industry.

CPA Calls on JPMorgan and Bank of America to Withdraw from CATL IPO

CPA Calls on JPMorgan and Bank of America to Withdraw from CATL IPO

The IPO, widely seen as the first major test of President Trump’s America First Investment Policy (AFIP), directly undermines the President’s February directive to block U.S. investment in companies linked to the Chinese military, human rights abuses, and authoritarian surveillance state.

CPA Applauds Commerce Department’s Final Determinations Confirming China’s Rampant Trade Violations in Solar Imports from Southeast Asia

CPA Applauds Commerce Department’s Final Determinations Confirming China’s Rampant Trade Violations in Solar Imports from Southeast Asia

The Department’s decision confirms what CPA has consistently warned: Chinese solar companies have been illegally circumventing U.S. trade laws through Southeast Asian shell operations, flooding the U.S. market with dumped and subsidized products directly harming the domestic solar manufacturing industry.